Skip to main content

A Phase 1 Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Doses of PF-06940434 in Patients with Advanced or Metastatic Solid Tumors

Clinical Trial Grant
Duke Scholars

Administered By

Duke Cancer Institute

Awarded By

Pfizer, Inc.

Start Date

March 17, 2021

End Date

August 31, 2025
 

Administered By

Duke Cancer Institute

Awarded By

Pfizer, Inc.

Start Date

March 17, 2021

End Date

August 31, 2025